Ozempic produces NASH resolution without worsening fibrosis

Patients treated with subcutaneous Ozempic experienced better resolution of non-alcoholic steatohepatitis without worsening fibrosis, according to the results of a placebo-controlled study presented at The Liver Meeting Digital Experience.In his presentation, Phillip N. Newsome, PhD, from the Birmingham Biomedical Research Centre in the United Kingdom, said a glucagon-like peptide-1 analog, like Ozempic (semaglutide, Novo Nordisk), can impact appetite suppression, gastric emptying and glycemic control.“Semaglutide is the latest example of long-lasting GLP-1 analogs with a half-life ofRead More

Share on facebook
Share on twitter
Share on linkedin